Evicenter
MarkdownMedical informationP&T meetings
Darovasertib (IDE196)

First-line metastatic uveal melanoma, in combination with crizotinib

Also known as LXS196
Manufacturer
IDEAYA Biosciences
Launch
Not announced
Last updated
206 sources

Product information and disease descriptionProduct description

Phase of product development

23 evidence topics · 19 sources

Launch

No evidence found.

FDA acceptance, priority review, and action date

No evidence found.

Origin at Novartis and the 2018 license to IDEAYA
Servier license for rights outside the United States, August 2025
Cash, cash runway, and financing
OptimUM-02 topline results expected in the first quarter of 2026, January to March 2026, superseded in April 2026